INKT.US Mink Therapeutics Inc

Healthcare Biotechnology USA Stocks
9.34 USD
Close of Nov 15, 2026
8.48 16.93
Market cap
USD 47.9M
P/E
-
P/B
11.33x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is INKT.US undervalued?

Graham number

The Graham number of Mink Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Mink Therapeutics Inc fundamental analysis

No fundamental analysis for Mink Therapeutics Inc yet.

Mink Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Mink Therapeutics Inc

MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botens…

Full company profile